Innate Pharma S.A. is a biotechnology company focused on developing immunotherapies for cancer treatment. The company's pipeline centers on natural killer (NK) cell engagers and checkpoint inhibitors designed to enhance anti-tumor immune responses. Lead candidates include Lacutamab (IPH4102), an anti-KIR3DL2 antibody in Phase II trials for cutaneous and peripheral T-cell lymphomas, and Monalizumab, a checkpoint inhibitor in Phase III development for advanced solid tumors including colorectal, lung, and head and neck cancers. The company also advances earlier-stage programs targeting immunosuppressive pathways, including IPH5201 (anti-CD39), IPH5301 (anti-CD73), and multiple NK cell engagers such as IPH6401 (BCMA-targeting) and IPH6101 (NKp46-based).
Innate Pharma maintains licensing and collaboration agreements with major pharmaceutical companies including AstraZeneca, Sanofi, Novo Nordisk, and MedImmune, which provide development support and potential revenue streams. The company operates with 174 full-time employees and is headquartered in Marseille, France, with international operations supporting its clinical development activities. As a clinical-stage biotechnology company, revenue generation is primarily dependent on milestone payments and royalties from partnership agreements rather than product sales.
No 10-K filings found.